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ABSTRACT
Introduction Clinically complex patients often require 
multiple medications. Polypharmacy is associated 
with inappropriate prescriptions, which may lead to 
negative outcomes. Few effective tools are available to 
help physicians optimise patient medication. This study 
assesses whether an electronic medication management 
support system (eMMa) reduces hospitalisation and 
mortality and improves prescription quality/safety in 
patients with polypharmacy.
Methods and analysis Planned design: pragmatic, 
parallel cluster- randomised controlled trial; general 
practices as randomisation unit; patients as analysis unit. 
As practice recruitment was poor, we included additional 
data to our primary endpoint analysis for practices 
and quarters from October 2017 to March 2021. Since 
randomisation was performed in waves, final study design 
corresponds to a stepped- wedge design with open cohort 
and step- length of one quarter. Scope: general practices, 
Westphalia- Lippe (Germany), caring for BARMER health 
fund- covered patients. Population: patients (≥18 years) 
with polypharmacy (≥5 prescriptions). Sample size: 
initially, 32 patients from each of 539 practices were 
required for each study arm (17 200 patients/arm), but 
only 688 practices were randomised after 2 years of 
recruitment. Design change ensures that 80% power is 
nonetheless achieved. Intervention: complex intervention 
eMMa. Follow- up: at least five quarters/cluster (practice). 
recruitment: practices recruited/randomised at different 
times; after follow- up, control group practices may 
access eMMa. Outcomes: primary endpoint is all- cause 
mortality and hospitalisation; secondary endpoints are 
number of potentially inappropriate medications, cause- 
specific hospitalisation preceded by high- risk prescribing 
and medication underuse. Statistical analysis: primary 
and secondary outcomes are measured quarterly at 
patient level. A generalised linear mixed- effect model 
and repeated patient measurements are used to consider 
patient clusters within practices. Time and intervention 
group are considered fixed factors; variation between 
practices and patients is fitted as random effects. 
Intention- to- treat principle is used to analyse primary and 
key secondary endpoints.
Ethics and dissemination Trial approved by Ethics 
Commission of North- Rhine Medical Association. Results 
Strengths and limitations of this study
 ► We will provide evidence of the effectiveness of an 
electronic medication management support system 
in reducing mortality and hospitalisation in adult 
patients with polypharmacy in real- life general 
practice.
 ► The intervention concept is innovative, as it is the 
first time that information based on claims data is 
made available to general practitioners (in Germany) 
in the form of an electronic tool.
 ► However, claims- based outcome measures also 
have disadvantages, as data are collected for the 
purpose of reimbursement, which limits the choice 
of outcomes.
 ► A stepped- wedge cluster- randomised design with 
an open cohort will allow us to overcome insufficient 
recruitment.
 ► We included a time variable to adjust for confound-
ing time effects and overcome such methodological 
shortcomings of stepped- wedge design.
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will be disseminated through workshops, peer- reviewed publications, local 
and international conferences.
Trial registration NCT03430336.  ClinicalTrials. gov (https:// clinicaltrials. 
gov/ ct2/ show/ NCT03430336).
INTRODUCTION
Multiple medications are often required to manage clin-
ically complex patients. Clinicians are frequently chal-
lenged by the need to ensure that treatment of complex 
patients adheres to disease- specific clinical practice 
guidelines.
Polypharmacy, defined as the use of five or more medi-
cations,1 increases the potential for the prescription of 
potentially inappropriate medications (PIMs) due to the 
non- consideration of drug–drug or drug–disease inter-
actions, inappropriate dosages (perhaps due to the age 
of the patient) as well as unintended duplicate prescrip-
tions.2–6 The use of greater numbers of drug therapies has 
been associated with increased risk of adverse drug reac-
tions7 irrespective of age.8 It has also been associated with 
increased risk of hospital admissions,9–11 hip fractures in 
older adults12 and higher costs and mortality.10 11 13
In line with the increasing number and complexity of 
medications, polypharmacy is associated with reduced 
medication adherence in patients. It may also result in 
undertreatment, particularly in the elderly, in whom too 
few prescriptions and excessively low dosages have been 
reported.14–16
Medication errors and omissions are important prob-
lems facing routine care in general practice, especially 
in patients with multimorbidity and multiple prescrip-
tions.17–19 They may contribute to patient hospital admis-
sions and mortality, thus additional understanding of 
such incidents is required.20 As most medication errors 
and omissions are preventable, raising physicians’ aware-
ness of polypharmacy may help to ensure the safe, effec-
tive and appropriate use of medication.19 21 22
Medication management strategies allow patients and 
families to actively participate with their physicians in 
developing complete and accurate medication lists. To 
ensure patients receive high- quality healthcare, physi-
cians should be provided with tools that help them avoid 
risks in the treatment of their patients.22–24 Likewise, 
physicians should have access to continuously available 
data on quality- oriented aspects to support the control 
of their patients’ treatments.24 Few effective instruments 
are available to help physicians systematically monitor 
and optimise the medications their patients take.22 Such 
tools comprise computerised Decision Support Systems 
(CDSS) or complex multifaceted pharmaceutical care- 
based approaches that may incorporate CDSS as part 
of the intervention. CDSS are computer- based systems 
providing ‘passive and active referential information 
as well as reminders, alerts and guidelines’.25 A recent 
systematic review26 concluded that although CDSS may 
reduce PIMs, additional randomised controlled trials 
are needed to assess their impact on patient- relevant 
outcomes and to evaluate the use of medication targets 
such as the Screening Tool of Older People’s Prescrip-
tions and the Screening Tool to Alert doctors to the Right 
Treatment (START) criteria.27
Considering that individual, patient- related informa-
tion relevant for the drug therapy is currently unavailable 
to physicians and that there is a lack of instruments helping 
physicians to regularly review their patients’ medication, 
an intervention with a web- based medication manage-
ment system was developed within the Anwendung für 
digital unterstütztes Arzneimitteltherapie- Management 
(AdAM) project. The primary objective of the AdAM trial 
is, therefore, to assess whether such electronic medica-
tion management support system (complex intervention) 
reduces the combined endpoint of all- cause mortality and 
all- cause hospital admissions in patients with polyphar-
macy, compared with usual care and in the real context of 
a general practice setting. Substudies to be performed will 
include cost- effectiveness analysis, the analysis of barriers 
and facilitators through interviews and focus groups with 
practitioners and interviews with patients, a trial process 
evaluation as well as sustainability analysis and quality cost 
accounting systems to explore the relationship between 
organisational context, implementation process and 
quality of care (online supplemental additional file 1). 
However, as this study protocol focuses on the AdAM 
intervention, these substudies will not be explained in 
detail in this paper.
AIMS
The AdAM trial aims to:
1. Evaluate whether the complex intervention reduces 
the combined outcome of all- cause hospitalisation 
(including night- only and day- only admissions) and 
all- cause mortality (primary outcome) or any of its 
components (secondary outcomes) in patients with 
polypharmacy, compared with usual care.
2. Evaluate whether the complex intervention reduces 
cause- specific hospitalisation preceded by high- risk 
prescribing in patients with polypharmacy, compared 
with usual care (secondary outcomes).
3. Ascertain whether the complex intervention reduces 
the number of PIMs and Potential Prescribing Omis-
sions as measured using explicit criteria, in patients 
with polypharmacy, compared with usual care (out-
comes of process of care).
4. Assess whether the complex intervention reduces the 
number of prescribed medications in patients with 
polypharmacy, compared with usual care (outcomes of 
process of care).
5. Evaluate whether the complex intervention is effective 
in reducing the combined primary outcome, or any of 
its components, in subgroups of patients defined ac-
cording to age (<65 vs ≥65 years), sex, early and late 
enrolment (patient does or does not fulfil the inclu-
sion criteria from the moment he or she joins the inter-
vention of the associated practice) and main treating 
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physician (general practitioner—GP vs specialised 
physician or hospital outpatient clinics).
METHODS AND ANALYSIS
Study design
The AdAM trial was originally planned as a pragmatic, 
parallel cluster- randomised controlled trial (cRCT) with 
15 months (five quarters) of follow- up per cluster (prac-
tice). The general practice was the unit of randomisation 
and the patient the unit of analysis. Since GPs trained in 
performing the intervention are unable to provide usual 
care, a clustered design (practices as clusters) was chosen 
to reduce treatment group contamination.
Important changes after trial launch
When practice recruitment ended in June 2019, it became 
obvious that the target numbers of practices and patients 
would not be achieved. Extensive simulations were, there-
fore, conducted on the assumptions that the number of 
eligible patients was the same (39 per practice) in all 688 
randomised practices, that 60% of potential patients had 
enrolled and that the event rate in the control group 
would be constant in all quarters. After completing the 
simulation, we decided to change the design of the trial 
in such a way that a power of 80% could still be reached. 
The following changes were made and will be explained 
in detail in each section of the protocol: (1) primary and 
secondary outcomes will be measured at regular intervals 
over 12 quarters, rather than once after five quarters and 
(2) The statistical analysis will be adapted to take account 
of the new design.
All changes were made before data from the study 
population were analysed (figure 1).
Study setting and population
The trial is conducted in general practices in Westphalia- 
Lippe, Germany.
Inclusion criteria for trial sites (general practices)
All criteria had to be fulfilled:
 ► General practices provide health services to patients 
covered by the BARMER statutory health insurance 
fund (BARMER).
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 ► Physicians work as GPs and have specialised in general 
practice, internal medicine or in no particular field.
 ► Practices have at least 10 eligible patients.
 ► Practices have access to the Westphalia- Lippe Associa-
tion of Statutory Health Insurance Physicians (KVWL) 
website through a secure connection that can be used 
by both GPs and other medical staff (practice nurse 
and healthcare assistants).
 ► Investigators agree to fulfil the contractual obligations 
arising from the trial.
Inclusion criteria for patients
All criteria had to be fulfilled:
 ► Patients are at least 18 years of age and covered by 
BARMER.
 ► They have polypharmacy, defined as the regular 
intake of at least five drugs (≥ five different Anatom-
ical Therapeutic Chemicals—ATC) in at least one 
quarter of the previous year. Each of the five ATCs has 
to be prescribed over at least two consecutive quarter 
in the previous year.
In order to participate in the intervention, patients 
had to provide written informed consent (online supple-
mental additional file 2). They also had to be competent 
to sign the required documents under law and capable 
of providing written informed consent to participate in 
the trial voluntarily. Patients who were not competent to 
sign the documents under law and were not capable of 
providing written informed consent to participate in the 
trial voluntarily (eg, because of dementia) could provide 
written informed consent signed by an informal caregiver.
No changes were made to setting and study population 
after trial launch
Recruitment and registration
Recruitment and registration of practices
The KVWL and the BARMER provided a list of general 
practices that were eligible to participate in the trial. Of 
these, the KVWL contacted GPs from practices with at 
least 10 eligible patients by postal mail (written invita-
tion). Reminders were later sent by fax. GPs who wished 
to participate had to return a signed investigator’s agree-
ment form to the KVWL (either by postal mail or fax).
Moreover, the trial was announced in journals and 
local media (press, radio, television) and communicated 
to local key stakeholders (moderators of quality circles, 
managers of practice networks, etc). Local recruitment 
events were also organised.
Recruitment and registration of patients
STEP 1: before randomisation and quarterly during the 
intervention period, the BARMER identified eligible 
patients from the participating general practices based 
on claims data.
STEP 2: after cluster- randomisation of participating 
practices, patients in the intervention practices were 
recruited in three ways:
 ► Every quarter, GPs received a list of eligible patients 
as well as written information and informed consent 
forms for the patients. The GPs could, therefore, 
invite eligible patients on their lists to participate.
 ► The BARMER sent written information on the study 
(information letter and a flyer) to eligible patients 
from participating intervention practices, so that they 
could actively approach their GPs to find out about 
the study. The aim was to explain the contents of the 
AdAM project to eligible patients in good time in 
order to arouse interest and actively assist in enrol-
ment. The BARMER telephone hotline was available 
to immediately answer any questions the patients had. 
Additional information on the study was provided 
on the BARMER website (daily news and Frequently 
Asked Questions (FAQ) list).
 ► GPs invited patients from their practices that fulfilled 
the inclusion criteria but had not (yet) been identi-
fied as eligible from claims data (eg, due to a delay of 
data processing).
STEP 3: GPs sent patients’ written informed consent 
to the KVWL. The KVWL digitised the consent forms 
and transmitted them to BARMER for verification of 
insurance status. When the results were positive, KVWL 
permitted GPs to access the electronic medication 
management support system (eMMa) and forwarded the 
original consent forms to the BARMER for archiving.
When the follow- up period of the cRCT was over, 
eligible patients in the control group that were identified 
in STEP 1 were invited to provide their written informed 
consent and participate in the intervention. Beginning 
with STEP 2, the recruitment and registration of control 
patients followed the same procedure as intervention 
patients (figure 1).
No changes were made in recruitment and registration 
after the trial began
Randomisation and allocation concealment
Practices were randomly allocated to the complex inter-
vention or control arm in a ratio of 1:1 (figure 2). Balanced 
randomisation was performed every month to ensure 
that the treatment groups were of approximately equal 
size for each quarter. The KVWL provided lists of partic-
ipating practices to the Department of Medical Infor-
matics, Biometry and Epidemiology (AMIB) at the Ruhr 
University Bochum, Germany. A study- independent staff 
member at the AMIB used computer- generated random 
numbers to generate randomisation lists from the list of 
participating practices. Randomisation lists were sent to 
KVWL, which concealed treatment allocation to partic-
ipating practices. Once a practice was randomised, all 
eligible patients at the practice were deemed to be inter-
vention or control patients, depending on the arm of the 
study the practice was allocated to. The first list of eligible 
patients in the intervention group was made available to 
participating physicians and the intervention began, after 
patients had signed the informed consent form. Eligible 
patients in the control group continued to receive usual 
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care. After signing the informed consent form, eligible 
patients in the control group were invited to participate 
in the intervention five quarters after the start of the 
intervention at the other practices from the same rando-
misation wave.
No changes were made in randomisation and alloca-
tion concealment after the trial began
Blinding
Allocation was disclosed to the practices soon after rando-
misation and to patients from intervention practices 
when they were asked to provide their written informed 
consent. Patients in the control group were not aware of 
the study until the end of their practice’s follow- up period 
of the cRCT.
Due to the type of intervention, neither GPs and their 
patients nor the AdAM study team was blinded to the 
treatment allocation.
No changes were made in blinding after trial 
commencement
Treatment plan for intervention and control groups
Intervention group
Several key elements of the intervention must be put into 
place in participating general practices:
1. The web- based, user- initiated CDSS eMMa provides the 
GP with drug–therapy information that is relevant to 
participating patients with polypharmacy on demand. 
The information might include data on diagnoses, 
treatments (also non- pharmacologic, such as physio-
therapy) and medical products (eg, assistive devices). 
The information is based on claims data gathered from 
all healthcare professionals involved in the care of the 
patient (eg, specialised ambulatory care physicians, 
other GPs, psychotherapists as well as data on hospital 
stays and prescription data from pharmacies). RpDoc 
Solutions GmbH developed eMMa in collaboration 
with KVWL.
2. GPs can add and modify patient data in eMMa (eg, re-
move drugs that the patient no longer takes, add new 
diagnoses, prescriptions and over the counter (OTC) 
drugs and recent laboratory findings about kidney 
function, etc) in order to enhance and update relevant 
information.
3. Aided by eMMa, GPs systematically assess the appro-
priateness of every patient’s medication at least once 
a year. Alerts will draw the GP’s attention to possible 
drug–drug interactions, drug–disease interactions, 
age- related PIMs, duplicate medications, renal dose 
adjustments, allergies, as well as general inappropriate-
ness, such as prescriptions associated with Dear Doctor 
letters (Rote- Hand- Briefe) and QT prolongation (for 
a detailed description see online supplemental addi-
tional file 3).
4. GPs optimise patient medication.
5. GPs print out the updated medication plan, which in-
cludes recommendations on medication use, reasons 
for prescriptions in lay language, and information on 
drugs that should be avoided, and hand it out to pa-
tients. The plan will also be available in foreign lan-
guages for patients that speak poor German.
6. eMMa provides GPs with guidance (eg, recommen-
dations addressing certain types of medication errors 
and high- risk prescribing that were developed by the 
German Society for Internal Medicine in collaboration 
with other scientific medical societies).
Intervention training
GPs were invited to attend two kick- off meetings and a 
decentralised event on polypharmacy with a consulting 
pharmacist from KVWL.
Figure 2 AdAM data availability (time flow). AdAM, Anwendung für digital unterstütztes Arzneimitteltherapie- Management; 
cRCT, cluster- randomised controlled trial.
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GPs and healthcare assistants also could attend a decen-
tralised software training event with consulting pharma-
cists and IT support staff.
The KVWL has made a training video and an FAQ list 
for participating practices available on the trial access site.
During practice hours, several telephone hotlines 
were offered for technical questions (IT support) and to 
provide on- site support for questions relating to adminis-
tration, management and use.
The Template for Intervention Description and Repli-
cation (TIDieR) checklist was used to ensure that the 
intervention reporting standards were met (online 
supplemental additional file 4).
No changes were made to the experimental treatment 
after the trial commenced.
Control group
For the duration of the cRCT, patients in the control group 
continued to receive usual treatment from their GP. Five 
quarters after the start of the intervention at the other 
practices from the same randomisation wave, control 
practices could switch to intervention and the patients 
in these practices had the option to switch to the inter-
vention group on condition that they first provide their 
written informed consent to receive the intervention.
No changes were made concerning the control group, 
as the switch to the intervention group was already 
planned in order to carry out the substudy on sustain-
ability (see online supplemental additional file 1).
Outcome assessment
Primary outcome
The primary outcome is the combined endpoint of all- 
cause mortality and all- cause hospitalisation (including 
night- only and day- only admissions) in patients with poly-
pharmacy, as assessed quarterly (table 1).
Secondary outcomes
1. All- cause hospitalisation (quarterly): to evaluate 
whether the complex intervention reduces all- cause hospi-
talisation (including day- only or night- only admissions) 
(number and duration) in patients with polypharmacy 
(table 2).
2. All- cause mortality (quarterly): to assess whether 
the complex intervention reduces all- cause mortality in 
patients with polypharmacy (table 3).
3. Incidence rate of cause- specific hospitalisation 
preceded by high- risk prescribing (quarterly): to evaluate 
whether the complex intervention reduces cause- specific 
hospital admissions (gastrointestinal bleeding, heart 
failure, renal failure, fall- related fractures or injuries; 
including and excluding day- only admissions) preceded 
by high- risk prescribing in patients with polypharmacy 
(table 4).
Secondary outcomes concerning process of care
4. Number of PIMs (quarterly): to ascertain whether the 
complex intervention improves the appropriateness of 
prescriptions in patients with polypharmacy (tables 5 and 
6).
5. Total number of underused medications (quarterly): 
to assess whether the total number of underused medica-
tions (based on the modified START criteria) in patients 
with polypharmacy does not increase in the intervention 
group in comparison to the control group (table 7).
6. Total number of prescribed medications (quarterly): 
To assess whether the complex intervention reduces the 
total number of prescribed medications in patients with 
polypharmacy (table 8).
Data for primary and secondary outcomes will be taken 
from health insurance claims data (BARMER) for the 
period from the fourth quarter 2017 to the first quarter 
2021.
Changes made after trial commencement: initially, we 
planned a one- time survey of outcomes for a period of 
five quarters following randomisation. In the end, data 
on the endpoints were collected quarterly for the period 
from the fourth quarter 2017 to the first quarter 2021.
See online supplemental additional file 5 for more 
information about the secondary outcome measures.
Explanatory variables for population characteristics
Patient (first level) variables
 ► Sociodemographic patient data: sex, age, insurance 
status and reason insurance coverage ended (death, 
change of sickness fund).
 ► Outpatient diagnoses and outpatient services: the 
International Classification of Diseases 10th edition 
codes28 are used for the outpatient diagnoses, which 
are documented on a quarterly basis. The services 
are coded according to the Physician’s Fee Scale 
(Einheitlicher Bewertungsmaßstab).
 ► Medication: drugs are identified using their national 
drug code (pharmaceutical registration number, 
Table 1 Primary outcome measure—CPO—all- cause 
mortality and all- cause hospitalisation
Number Outcome
CPO- 1 All- cause mortality and all- cause hospitalisation 
(including emergency admissions).
CPO, composite primary outcome.
Table 2 Secondary outcome measures—hospitalisation* 
(SOh)
Number Outcome
SOh- 1 All- cause hospitalisation.
*Hospitalisation includes day and night admissions (emergency admissions) 
combined and separately.
Table 3 Secondary outcome measure—mortality (SOm)
Number Outcome
SOm- 1 All- cause mortality.
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Pharma- Zentral- Nummer—PZN), which contains all 
relevant information such as trade name, active chem-
ical ingredient(s), strength, application, dosage and 
indication. The PZN will be linked to the ATC Clas-
sification System, which allows analysis to be based 
on active ingredients, manufacturer and package 
Table 4 Secondary outcome measures—cause- specific hospital admissions (SOh)
Number Outcomes
Cause- specific hospital admissions preceded by high- risk prescribing
  SOh- 2 Hospital admissions due to GI bleeding or ulcers in patients at risk for medication- related GI disorders (defined in SOpim 1–8 measures) 
in the 12 weeks before admission.33
  SOh- 3 Hospital admissions due to acute heart failure or acute renal failure in patients at risk for medication- related cardiovascular disorders 
(defined in SOpim 9–17 measures) in the 12 weeks before admission.33
  SOh- 4 Hospital admissions due to fall- related fractures or injuries in patients who were at risk for medication- related falls (defined in SOpim 
18–19 measures) in the 12 weeks before admission.
Cause- specific hospital admissions not preceded by high- risk prescribing
  SOh- 5 Hospital admissions due to GI bleeding or ulcer in patients who were not at risk for medication- related GI disorders (defined in SOpim 
1–8 measures) in the 12 weeks before admission.
  SOh- 6 Hospital admissions due to acute heart failure or acute renal failure in patients who were not at risk for medication- related 
cardiovascular disorders (defined in SOpim 9–17 measures) in the 12 weeks before admission.
  SOh- 7 Hospital admissions due to fall- related fractures or injuries in patients who were not at risk for medication- related falls (defined in SOpim 
18–19 measures) in the 12 weeks before admission.
Table 5 Secondary outcome measures—PIM- related high- risk prescribing (SOpim)
Number Outcomes
High risk of GI bleeding
  SOpim- 1 Patients with a peptic ulcer, GERD, Crohn’s disease or gastritis who were prescribed a traditional oral NSAID* without a 
gastroprotective drug.33 34
  SOpim- 2 Patients aged ≥65 who were prescribed a traditional oral NSAID* without a gastroprotective drug.33
  SOpim- 3 Patients prescribed a platelet aggregation inhibitor excluding heparin and a traditional oral NSAID* without a gastroprotective drug.33 
34
  SOpim- 4 Patients prescribed a fixed combination of aspirin and clopidogrel or aspirin and either clopidogrel, ticagrelor or prasugrel without a 
gastroprotective drug.33
  SOpim- 5 Patients prescribed an oral anticoagulant or a direct thrombin inhibitor or a direct factor Xa inhibitor and a traditional oral NSAID* 
without a gastroprotective drug.33 34
  SOpim- 6 Patients prescribed an oral anticoagulant and a platelet aggregation inhibitor excluding heparin without a gastroprotective drug.33 34
  SOpim- 7 Patients prescribed SSRI or SSNRI with a traditional oral NSAID* without a gastroprotective drug.35 36
  SOpim- 8 Patients prescribed a systemic glucocorticoid with a traditional oral NSAID* without a gastroprotective drug.35
High- risk cardiovascular prescribing
  SOpim- 9 Patients prescribed an ACE inhibitor/ARB/renin inhibitor with an oral NSAID*.33 34
  SOpim- 10 Patients prescribed a diuretic with an oral NSAID*.33 34
  SOpim -11 Patients with heart failure prescribed any oral NSAID*.33 34
  SOpim- 12 Patients with heart failure prescribed a tricycle antidepressant.35 37
  SOpim- 13 Patients prescribed an ACE inhibitor/ARB/renin inhibitor or a potassium- sparing diuretic including aldosterone antagonists with a 
potassium supplement.34 35 37
  SOpim- 14 Patients with heart failure prescribed a beta- blocking agent, non- selective.37
  SOpim- 15 Patients aged ≥65 prescribed a QTc prolongation drug.38 39
  SOpim- 16 Patients prescribed two or more QTc prolongation drugs or a QTc prolongation drug with an inhibitor of its isozyme (CYP3A4, 
CYP2D6) or with known risk factors (heart failure, bradycardia, sick sinus syndrome including tachycardia- bradycardia syndrome, 
other cardiac arrhythmias including long- QT syndrome).38 39
  SOpim- 17 Patients prescribed digitalis glycosides with a non- potassium- sparing diuretic and no potassium supplement.34
High- risk prescribing with regards to falls
  SOpim- 18 Patients aged ≥65 prescribed a drug that increases risk of falling.38
  SOpim- 19 a/b Patients with Parkinson’s disease or other degenerative diseases of basal ganglia prescribed a drug that increases risk of falling.38
High- risk prescribing is related to prescriptions in the previous 12 weeks.
*Information related to NSAID is based on claims data; over- the- counter medications cannot be measured.
ACE, angiotensin- converting enzyme; ARB, angiotensin receptor blocker; GERD, gastroesophageal reflux disease; NSAID, non- steroidal anti- inflammatory drug; 
QTc, corrected QT interval; SRNI, serotonin and norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitor.
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size. The duration of the therapy will be assessed by 
means of the defined daily dose and included in the 
reference table. The data set only includes prescribed 
medication that is paid for by the insurance fund.
 ► Inpatient data: for each hospitalisation, the start and 
end date, the admission and discharge diagnosis 
(with date), as well as secondary diagnoses, will be 
available. Furthermore, operations and treatment 
procedures are also documented (Operation and 
Procedure—Code).
 ► Long- term nursing care (Sozialgesetzbuch): for 
patients receiving long- term nursing care, the start 
and end date, the level and place of care, the costs 
and type of services (cash, non- cash, combined) are 
documented in the data set.
Practice profile (second level) variables
 ► Single- handed practice/group practice (including 
ambulatory healthcare centres, along with the number 
of physicians).
 ► Work experience (start and end date of practice 
according to KVWL data).
 ► Practice size: number of registered patients in most 
recent quarter.
 ► Participation in a (regional) practice network.
GP profile (second level) variables
 ► Age, gender.
No changes were made to explanatory variables
Safety monitoring and adverse events
Safety and adverse events were not monitored and 
reported on, since it was assumed that treatment could 
not deteriorate as a result of the trial. The study team 
had no influence on the diagnostic–therapeutic decision- 
making of GPs and their patients, and analysis of the 
pseudonymous data will be conducted with a significant 
delay. GPs and patients could, therefore, not be informed 
of identified medication errors.
Table 6 Secondary outcome measures—PIM- related high- risk prescribing composite (SOpim)
Number Outcomes
High- risk prescribing composite
  SOpim- 20 Patients with any risk factor and one or more high- risk prescriptions as defined in SOpim measures 1–8. GI risk composite
  SOpim- 21 Patients with any risk factor and one or more high- risk prescriptions as defined in SOpim measures 9–17. V risk composite
  SOpim- 22 Patients with any risk factor and one or more high- risk prescriptions as defined in SOpim measures 18–19. Fall risk composite
  SOpim- C Patients with any risk factor and one or more high- risk prescriptions as defined in SOpim measures 20–22. High- risk prescription
Initiation and discontinuation prescription measures
  SOpim- Ci Patients who were not exposed to high- risk prescriptions (as defined in SOpim- C measures) in the 12 weeks 
previous to the intervention (as defined by date of the intervention invoice) and who received a high- risk 
prescription (as defined in SOpim- C measures) within 12 weeks of the beginning of the intervention.
Initiation of high- risk 
prescriptions
  SOpim- Cd Patients who were exposed to a high- risk prescription (as defined in SOpim- C measure) in the 12 weeks 
previous to the intervention (as defined by date of the intervention invoice) that did not receive a high- risk 
prescription within 12 weeks of the beginning of the intervention.
Discontinuation of 
high- risk prescriptions
CV, cardiovascular; PIM, potentially inappropriate medication.
Table 7 Secondary outcome measures—underused medication (SOum)
Number Outcomes
Underused medication
  SOum- 1 Patients with chronic atrial fibrillation who were not prescribed vitamin K antagonists or direct thrombin inhibitors or direct factor Xa 
inhibitors in the previous 12 weeks.27
  SOum- 2 Patients with coronary, cerebral or peripheral vascular disease who were not prescribed an antiplatelet therapy (aspirin or clopidogrel or 
prasugrel or ticagrelor).27
  SOum- 3 Patients with ischaemic heart disease who were not prescribed a beta- blocker.27
  SOum- 4 Patients who were prescribed methotrexate without a folic acid supplement in) the previous 12 weeks.27
  SOum- 5 Patients who were receiving opioids regularly without laxatives in the previous 12 weeks.27
  SOum- 6 Patients with systolic heart failure and/or documented coronary artery disease who were not prescribed ACE inhibitors or ARB.27
  SOum- 7 Patients with stable systolic heart failure who did not receive appropriate beta- blockers (bisoprolol, nebivolol, metoprolol or carvedilol).27
  SOum- 8 Patients not regularly taking an inhaled β2 agonist or antimuscarinic bronchodilator for mild to moderate asthma or COPD.27
  SOum- 9 Patients not regularly taking an inhaled corticosteroid for moderate- severe asthma or COPD.27
  SOum- 10 Patients with diabetes with or without serum biochemical renal impairment who did not receive ACE inhibitors or ARB (if intolerant of ACE 
inhibitors).27
ACE, angiotensin- converting enzyme; ARB, angiotensin receptor blocker.
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Unintended consequences of using the e- Health tech-
nology such as non- acceptance will be investigated quali-
tatively (online supplemental additional file 1).
Data collection and management
Data collection
Information on all eligible patients was taken pseudon-
ymously from BARMER’s claims data. Claims data detail 
billable interactions (insurer claims) between the insured 
patients and the healthcare delivery system.
In the trial, the KVWL data are not systematically linked 
to BARMER’s data on either a practitioner or patient 
level. The KVWL provides sociodemographic data on 
GPs and practice profiles for both the intervention and 
control groups.
Data management
The required claims data for all eligible patients in the 
region covered by the KVWL will be specified in a coor-
dinated Minimum Data Set (MDS) and prepared by the 
PMV research group in Cologne.
The trial data will be archived for 10 years. BARMER 
will archive a back- up copy containing the data of all study 
patients (list of eligible patients, declarations of consent 
to participate in the trial and on data protection, signed 
and dated by the patients as well as the data provided for 
the evaluation) in accordance with European basic data 
protection regulations. The KVWL will archive documents 
concerning the general practices/GPs participating in 
the trial (eg, signed investigator’s agreement form). The 
Institute of General Practice (IGP) will archive the trial 
master file and any related study plans (MDS and statis-
tical analysis plan). The data provided by KVWL and 
eMMa, as well as primary data collected in interviews with 
patients, will be archived by the IGP in accordance with 
European basic data protection regulations.
End of the trial
The regular end of the intervention and follow- up period 
for all patients was March 2021.
A patient’s participation in the intervention ends 
prematurely: (1) when he or she switches to another 
insurance company and/or a non- participating practice 
or (2) the GP withdraws his or her consent or is no longer 
licensed to provide health services by the KVWL.
Schedule and duration of the trial
Practice recruitment: 2 May 2017 to 30 June 2019.
Intervention period: 15 February 2018 to 31 March 
2021.
Claims data from 1 January 2017 to 31 March 2021 will 
be used in the analysis. The cohort is open, meaning that 
patient data are included from the quarter in which the 
inclusion criteria are met.
Quality control and quality assurance
The principal investigator and a steering committee 
(comprising representatives of BARMER, KVWL and the 
evaluation team) guarantee that all processes in the trial 
comply with Good Clinical Practice (GCP) guidelines and 
ethical and legal requirements.
BARMER and the KVWL are responsible for moni-
toring the trial and were in particular responsible for 
the recruitment of practices and patients, randomisation 
(supported by the AMIB), the implementation of the 
intervention and the provision of data to the evaluation 
team.
A designated advisory board provides advice on ques-
tions concerning planning, conducting and analysing the 
trial.
Changes to data collection and data management: initially, 
data collection for each practice was to be carried out as 
a one- time survey to take place after the start of randomi-
sation and over a period of five quarters. In the end, data 
were collected at regular intervals over 12 quarters from 
the fourth quarter 2017 to the first quarter 2021 (light 
blue and light red areas in figure 2).
Sample size
Initially, based on data detailing the incidence of hospi-
talisation and all- cause mortality in patients with multiple 
prescriptions, we expected rates of 30% in the control 
group over a 12- month follow- up period.16 17 Based on 
a duration of 15 months (five quarters), the rates were 
assumed to be 35.25% in the control group, with a relative 
reduction of 5% in the intervention group. Based on 80% 
recruitment of practices and patients and an intra- cluster 
correlation coefficient of 1%, a sample size of 17 200 
cluster- randomised patients per group (539 practices per 
study arm, about 32 patients per practice) is required to 
detect an absolute difference in the combined endpoint 
of 1.8% between intervention and control groups (type 1 
error of 5% and type 2 error of 15%).
Changes made after trial launch: at the end of practice recruit-
ment in June 2019, it became clear that the target numbers 
of practices could not be achieved. In the period from 27 
June 2017 to 03 July 2019, 688 practices were randomised to 
the intervention and control groups. Based on the assump-
tions of 26 832 (688*39) eligible patients in the randomised 
practices, a participation rate of 60% of patients in the 
intervention group, the same number of practices at all 
changeover times (ie, the switch from control to interven-
tion group) and a constant event rate in the control group 
over all quarters, a power of 80% is achievable.
Statistical analysis
Population for analysis
As both patients who met the inclusion and exclusion 
criteria from the beginning and patients who fulfilled 
Table 8 Secondary outcome measures and process 
measures—polypharmacy indicators (SOp)
Number Outcomes
SOp- 1 Number of prescriptions per patient
Testing of these outcomes will be exploratory.
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the inclusion and exclusion criteria after the trial had 
commenced were able to receive the intervention, the 
ITT population was an open cohort. Patients from partici-
pating practices, therefore, started from the time at which 
inclusion and exclusion criteria were met during a period 
stretching from the fourth quarter 2017 to the end of the 
first quarter 2021. Following the ITT principle, practices 
and their patients will be analysed quarterly, according 
to the group to which the practice was allocated, regard-
less of whether they refused or discontinued the allocated 
treatment, or whether there were other deviations from 
the protocol.
For the efficacy analysis, only patients who were selected 
from the intervention group and for whom the GP had 
performed the intervention will be considered. This 
subgroup will be compared with patients in the control 
group that started the intervention after completion of 
the cRCT phase. In this population, it will be possible to 
estimate the maximum possible effect of the interven-
tion, comparable to a per- protocol population.
No changes were made to the population for analysis.
Statistical hypotheses, methods and analyses
The primary objective of this study is to determine 
whether the complex intervention reduces the combined 
endpoint of all- cause mortality and all- cause hospitalisa-
tion (including night- only and day- only admissions) in 
adult patients with polypharmacy, as compared with usual 
care. Statistically, the study objective is formulated as a 
test of the null hypothesis H0: p1=p2 (the two groups do 
not differ in terms of the quarterly event probability of 
combined endpoint pi, where i=1 or 2 for intervention or 
control group, respectively), compared with the alterna-
tive hypothesis H1: p1≠p2 (there is a difference between 
the two groups).
The analysis is based on quarterly data at a patient level 
and patients are clustered in practices. We will adjust for 
the different observation periods and for clustering in the 
data by fitting an appropriate generalised linear mixed 
model (GLMM). A mixed logistic regression model will, 
therefore, be used for all binary outcomes, and especially 
for the primary endpoint.
Time and treatment group and further confounders 
such as age, sex, the medCDS prognostic index,29 care 
level/degree at baseline, days in hospital in the 12 months 
preceding baseline are considered to be fixed factors. 
Since all practices were observed under both control and 
intervention conditions, it will be necessary to include 
two correlate random cluster- level effects in the model. 
To gauge the interdependence of individual measure-
ments OTC of the study, additional uncorrelated random 
effects for patients will also be fitted.
In the AdAM trial, we have assumed that the inter-
vention requires an initial period of adjustment before 
becoming fully embedded. The intervention effect is, 
therefore, expected to gradually increase from the time 
the practice switches to the intervention (¼ in the quarter 
of the practice change, ½ in the quarter after the change 
to intervention and the full effect thereafter).
A similar approach will be used to investigate secondary 
outcomes, sensitivity and efficacy.
The secondary outcomes 2 (all- cause hospitalisation) 
and 3 (all- cause mortality) are to be analysed hierarchi-
cally, reflecting the rationale of the intervention, with a 
significant decrease in the combined primary endpoint of 
all- cause mortality and all- cause hospital admissions (level 
1) expected to reflect primarily in a decline in all- cause 
hospitalisation (level 2). If so, all- cause mortality may also 
decrease (level 3). Therefore, the prespecified secondary 
outcomes 2 and 3 will be tested in a confirmatory manner. 
If no significant differences occur at any level, tests of 
outcomes on higher levels will be exploratory.
The baseline characteristics of participating practices, 
GPs and patients will be described according to the 
initially allocated treatment arm. Categorical data will be 
presented as frequencies and percentages. Total numbers, 
mean, SD, median, IQR, minimum and maximum will be 
provided for continuous data.
All statistical tests will be two sided at a significance 
level of α=0.05. No interim analysis of efficacy will be 
performed.
Changes made after trial launch: we initially planned to use 
a GLMM to evaluate the treatment effect in a randomised 
parallel group design. In addition to considering the 
treatment group to be a fixed factor, a random effect to 
account for clustering patients in practices is necessary. 
Due to the switch to a stepped- wedge design, a more 
complex model structure was required (see above).
Patient and public involvement
This protocol was developed without patient or public 
involvement.
ETHICS AND DISSEMINATION
The project is being carried out in accordance with the 
Medical Association’s code of conduct and GCP, and in 
line with the World Medical Association Declaration of 
Helsinki.30 The study plans and all patient- related docu-
ments have been sent to and approved by the Ethics 
Commission of the North- Rhine Medical Association 
(approval date 26 July 2017, approval number 2017184).
All changes made and reported here after the trial 
began have also been sent to and approved by the above- 
mentioned ethics committee (approval date 3 April 2020, 
approval number 6000207769).
The voluntary participation of practitioners in the trial 
is recorded in writing following their informed decision. 
Patients were asked for their consent as soon as the prac-
tice switched to the intervention. Patients who did not 
wish to participate continued to receive usual care.
Data protection is guaranteed for all patient- related 
data. Eligible patients were identified using pseudon-
ymous claims data from BARMER, whereby BARMER 
previously informed the patient of the opportunity to 
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participate in the trial. Before the intervention began, 
patients were separately informed about data protec-
tion during the trial and intervention. Patients had to 
provide their informed consent by signing and dating a 
declaration.
This study protocol was prepared in accordance with 
the extension of the Consolidated Standards of Reporting 
Trials 2010 statement for reporting on cluster randomised 
trials (online supplemental additional file 6)31 and the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials 2013 statement for reporting on clinical 
trial protocols (online supplemental additional file 7).32
We will prepare presentations to disseminate the study 
findings to healthcare stakeholders and patients, and at 
relevant national and international conferences. We aim 
to publish the results of the trial in peer- reviewed journals.
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Additional file 1. Brief description of AdAM sub-studies 
SUB-STUDY BIELEFELD. HEALTH-ECONOMIC ANALYSIS. 
The aim of this sub-study is to estimate the cost-effectiveness of the AdAM intervention 
compared to usual care.  
The economic analysis will be conducted from a third-party payer perspective, which is the 
perspective of the statutory health insurance funds in Germany. Health effects will be measured 
by use of the composite endpoint of the clinical study combining hospital admissions and deaths.  
The analysis of all reimbursed direct health care costs will be based on health insurance claims 
data comprising details on physician visits, inpatient hospital stays, pharmaceuticals 
(prescription medication), outpatient health care services provided by non-physicians and 
therapeutic appliances, rehabilitation, and sick pay. Arising costs, such as costs of IT-
infrastructure, coordination, maintenance, training and fees, will be used to estimate the overall 
costs of the AdAM intervention. Fees for physicians will be varied in sensitivity analysis. 
The cost-effectiveness of the intervention will be measured by the incremental cost-
effectiveness ratio (ICER), which is expressed as the ratio of the difference in overall costs 
between the control and the intervention group and the difference in effects between both 
groups. For the ICER calculation of the base case, mean values of costs and effects will be used. 
In sensitivity analysis, also median values will be used.  
Further analyses will be based on the composite endpoint’s components (hospital admissions 
and deaths), on life years gained (LYs), and on quality-adjusted life years (QALYs). To determine 
the LYs, the remaining life expectancy in both the control and intervention group will be 
estimated using mortality tables. In order to take into account differences in quality of life 
between ages when calculating QALYs, age-dependent utility values will be obtained from the 
literature. 
All future costs and health effects will be discounted by 3% per year according to 
recommendations by the German institute for efficiency and quality in health care (IQWiG). In 
sensitivity analysis, the discount rate will be varied from of 0% to 5%.
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SUB-STUDY KÖLN. ANALYSIS OF BARRIERS AND FACILITATORS: QUALITATIVE INTERVIEWS 
AND FOCUS GROUPS WITH PHYSICIANS. 
The aim of this sub-study is to identify factors facilitating or hindering the successful 
implementation of the intervention from a general practitioner’s point of view and evaluate 
which factors facilitate or hinder the effective performance of systematic medication-checks and 
optimization. Hereby is expected to get insights how the intervention can be optimized and 
adapted for general practitioners’ high-level acceptance and effectiveness of optimized 
medication-checks by area-wide implementation.  
Therefore a multistage mixed-methods-Approach will be conducted (combination of qualitative 
and quantitative outcomes) (1). 
Level 1: To analyze general practitioners subjectively perceived barriers and resources regarding 
implementation, guided expert-interviews will be conducted (n= 5-10) (face-to-face-interviews 
or telephone-interviews) (2,3) to explore the field. Therefore, a convenient sample strategy will 
be applied. Furthermore, formative evaluation will take part during the trial with two additional 
time points of qualitative data collection related to relevant emerging topics concerning 
successful implementation.  
Level 2: Results of qualitative data collection will be used for understanding practical orientation 
patterns of general practitioners (how do they actually use AdAM in real life settings) and their 
conjunctive experiential space (4). Focus groups with general practitioners of intervention and 
control group (total, n= 4) will be conducted concerning their experiences and expectations of 
the project.  
Level 3: Results of qualitative data collection will be used to prepare a quantitative general 
practitioners survey, in which all participating physicians of the intervention group will be asked 
about barriers and facilitators of the implementation. The survey aims representative detection 
of general practitioners factors, which facilitate or hinder implementation and identify specific 
attributes of ‘early adapters’ and ‘late adapters’ (5). Quantitative data will be evaluated 
descriptive and by applying appropriate multiple regression models. 
The quality of the qualitative research data collection and analysis in interviews and focus groups 
is assured by audio recording as well as by transcription according to established standards and 
by independent coding and subsequent interpretation by a group of researchers. Data analysis 
will comprise qualitative content analysis according to Kuckartz (6).  
Quality assurance concerning the survey conduct is assured by standards of survey 
development, pretesting, Dillman’s Total Design (7) method for increasing response rates and 
data preparation with the Teleform® software. 
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SUB-STUDY FRANKFURT. ANALYSIS OF BARRIERS, FACILITATORS AND UNINTENDED 
CONSEQUENCES: QUALITATIVE INTERVIEWS WITH PATIENTS 
The aim of this sub-study is to identify factors facilitating or hindering the successful 
implementation of the intervention. We especially focus on patient-perceived unintended 
consequences of the intervention, e.g. fear resulting from the exchange of information between 
several doctors or resentments towards the implemented technology.  
The sub-study starts after the positive ethics vote dedicated to the qualitative study has been 
received (second vote). Patients who have already received the intervention, can be included in 
the study (inclusion criterion: invoiced EBM-code). Patients will be recruited by their general 
practitioners. General practitioners are trustful “gatekeepers” with the potential to motivate 
patients to participate (8). After written informed consent, contact details will be forwarded to 
the Institute of General Practice in Frankfurt/Main. A target sample of 20 patients (balanced 
with regard to sex, age) out of two or more practices will be included in the study. 
We will interview the patients via telephone (9); the interviews are expected to take 20-40 
minutes each. The interviewer will use a semi-structured interview guide, which will be pilot-
tested in three to four think-aloud-interviews beforehand. Interviews will be audio recorded 
after informed consent and transcribed verbatim according to established standards (10). Data 
analysis will comprise qualitative content analysis according to Kuckartz (10). Data will be 
independently coded and subsequently interpreted by two researchers. The strategy of 
subsumption will be used to develop content categories mixed deductively-inductively. Data will 
be evaluated supported by software MAXQDA© at Goethe University in the Institute of General 
Practice in Frankfurt/Main. 
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ADAM PROCESS EVALUATION 
A process evaluation is an essential part of the evaluation of complex medical interventions. The 
process evaluation in AdAM will study the following aspects:  
1) Numbers of patients per practice from the list of potentially eligible patients that 
participated in AdAM (“reach”) 
2) Enrolment rate of GPs, general practices and patients measured as the number of GPs, 
general practices and patients per potentially eligible number of GPs, general practices and 
patients during the 15 months from baseline minus baseline (T1–T0) (“reach”). 
3) Number of patients per practice that were not included in the list of potentially eligible 
patients that participated in AdAM to evaluate the number of patients who benefit from the 
AdAM service. 
4) Quantitative aspects of the intervention: to which extent was the intervention eMMa® 
applied to patients (“dose”)? 
a. Number of GPs and general practices who use eMMa® to print a medication plan 15 
months (once a year and more than once a year) from baseline minus baseline (T1–
T0).  
b. Number of safety key figures retrievals and use of patient safety examination to 
ensure the frequency of use of eMMa® safety functionalities (BRAVO quality 
indicators). 
5) Qualitative aspects of the intervention: was the intervention eMMa® applied as planned 
(“fidelity”)? 
6) Adaptation of the intervention: which modifications were made to adjust the intervention 
to heterogeneous processes in participating practices (“tailoring”)? 
 
Software log files provided by RpDoc®Solutions GmbH will comprise the data needed for 
analyses. Pseudonyms will be used to prevent identification of individual patients, practices or 
doctors. 
Further details of the process evaluation (detailed research questions, MDS) will be provided a 
priori to the planned analyses. 
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ADAM SUSTAINABILITY ASSESSMENT 
A fading effect over time in interventions for the improvement of drug management has been 
mentioned in the literature (11). This sustainability assessment aims to analyze such temporary 
effects. The goal is to determine if improvements in the prescription of drugs due to eMMa® can 
still be found after more than five quartiles. Therefore, it is necessary for both the intervention 
group and the control group to receive the intervention, i.e. eMMa®.  
The sustainability assessment is meant to provide insights on the planned rollout on larger 
groups. Therefore, it is necessary for the control group to receive the full intervention.  
Any further details will be pre-specified in a separate protocol. 
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SUB-STUDY WUPPERTAL: QCAS TO EXPLORE THE RELATIONSHIP BETWEEN ORGANIZATIONAL 
CONTEXT, IMPLEMENTATION PROCESS AND QUALITY OF CARE 
The aim of this sub-study is to examine the process of effectiveness development, the 
interaction among key drivers (configurations of success) and to investigate, how these key 
drivers influence effect sustainability. The analyses of this sub-study will be based on practices 
of the intervention group of the parallel cluster-randomised controlled trial (c-RCT) and those 
practices of the control group who joined the intervention mode 15 months after their 
recruitment. We will include all control group practices who change intervention status at least 
until 30/06/2020. 
QCAs will be based on a conceptual model comprising contextual and implementation process 
factors affecting intervention’s effectiveness. Research suggests that attributes characterising 
the organisational context are important for the development of habitual behaviour and the 
successful adoption of interventions (12). In addition, contemporary definitions of organisations 
have evolved from a closed-system perspective (organisations = isolated systems with no 
interaction with their environment) to an open-system perspective. Therefore, organisational 
attributes will be defined on three distinct levels of analysis: 1) the behaviour of individuals, 2) 
the structural features and 3) the organisation viewed as an entity operating in a larger system 
of relations (13). 
Analytic methods 
In a first step, fuzzy set qualitative comparative analysis will be used to identify pathways – that 
is, different combinations of organisational attributes and implementation process 
characteristics – associated with: 
1. sites’ success in attaining a relative risk reduction in the primary end point at the end of the 
c-RCT (change is measured in comparison to the control groups’ results) – QCA 1,  
2. short term effects (change of secondary endpoints after the first five months of 
intervention) – QCA 2. 
In a second step, the findings of the first QCA will be integrated in a multilevel model (two-level 
HML) in which the cross-level interactions of the pathways will be investigated and mechanisms 
suited for reaching sustainability at the end of a three month follow-up phase will be explored.  
To prepare results of the first QCA for use in HLM, a categorisation of each study site as a 
member of one of the pathways is planned. Only those practices will be included in the 
multilevel model that are member of a configuration sufficient for outcome and part of c-RCT’s 
intervention group. To explore mechanisms suited for a sustainable intervention effect, the two-
level HLM will be estimated with the pathways (configurations) at the macro level. At the micro 
level a variable, which measures the stability of the attained performance level (dichotomous 
definition: “1” if there is no increase in all-causes hospital admissions and all-causes deaths per 
practice over the follow-up phase, otherwise “0”) will be included. As explanatory variables the 
four constructs of the normalisation process theory (NPT; coherence, cognitive participation, 
collective action, reflexive monitoring) will be considered. This construct will be measured at the 
beginning of the follow-up phase and by applying the instrument NoMAD (14). They will describe 
physicians’ views about how an intervention impacts on their work, and their expectations about 
whether it could become a routine part of their work. 
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Site sampling and data source: 
The first QCA and the multilevel model will include only practices of the intervention group. The 
second QCA will use practices of the control group as well, after this group has joined the 
intervention mode. 
Parameters corresponding to factors in the conceptual model will be derived from a survey, 
which is organised in two waves (first in 2019, second in 2020). The outcome measure will be 
based on secondary data (claims data). In addition, structural data of the practices (e.g. practice 
infrastructure, patient structure) and use of support will be obtained from other project partners 





BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-048191:e048191. 11 2021;BMJ Open, et al. Müller BS
REFERENCES 
 
1.  Mayring P. Evidenztriangulation in der Gesundheitsforschung. KZfSS Kölner Zeitschrift für 
Soziologie und Sozialpsychologie. 2017 Oct 10;69(S2):415–34.  
2.  Bogner A, Littig B, Menz W. Experteninterviews. Theorien, Methoden, 
Anwendungsfelder. 3., grundlegend überarbeitete Auflage. Wiesbaden: VS Verlag für 
Sozialwissenschaft; 2009.  
3.  Christmann G. Telefonische Experteninterviews. In: Alexander Bogner, Beate Littig und 
Wolfgang Menz (Hg): Experteninterviews Theorien, Methoden, Anwendungsfelder 3, 
grundlegend überarbeitete Auflage. Wiesbaden: VS Verlag für Sozialwissenschaften; 
2009.  
4.  Bohnsack R. Dokumentarische Methode und sozialwissenschaftliche Hermeneutik. 
Zeitschrift für Erziehungswiss. 2003;6(4):550–70.  
5.  Rogers EM. Diffusion of preventive innovations. Addict Behav. 2002 Nov;27(6):989–93.  
6.  Kuckartz U. Einführung in die computergestützte Analyse qualitativer Daten. Wiesbaden: 
VS Verlag für Sozialwissenschaften; 2007.  
7.  Dillman DA, Smmyth JS, Christian LM. Internet, phone, mail, and mixed-mode surveys: 
the tailored design method. Wiley; 2014. 528 p.  
8.  Helfferich F. Die Qualität qualitativer Daten. Manual für die Durchführung qualitativer 
Interviews, 3. Überarbeitete Auflage. Wiesbaden: GWV Fachverlage GmbH; 2009.  
9.  Flick U. Leitfaden-Interviews. In: Qualitative Sozialforschung Eine Einführung. 7th ed. 
Reinbeck bei Hamburg: Rowohlt; 2007. p. 194–226.  
10.  Kuckartz U. Qualitative Inhaltsanalyse. Methoden, Praxis, Computerunterstützung. 
Weinheim: Beltz Juventa; 2012.  
11.  Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, et al. A pharmacist-
led information technology intervention for medication errors (PINCER): a multicentre, 
cluster randomised, controlled trial and cost-effectiveness analysis. Lancet [Internet]. 
2012 Apr;379(9823):1310–9. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0140673611618175 
12.  Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering 
implementation of health services research findings into practice: a consolidated 
framework for advancing implementation science. Implement Sci. 2009 Dec 7;4(1):50.  
13.  Hogg W, Rowan M, Russell G, Geneau R, Muldoon L. Framework for primary care 
organizations: the importance of a structural domain. Int J Qual Heal Care. 2008 
Oct;20(5):308–13.  
14.  Finch T, Girling M, May C, Mair F, Murray E, Treweek S, et al. Nomad: Implementation 
measure based on Normalization Process Theory [Internet]. 2015 [cited 2018 Jan 25]. 




BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-048191:e048191. 11 2021;BMJ Open, et al. Müller BS
 
 
Version 1.0 Stand 3.7.2017  1 
 
 
Patient information  
Application of an electronic medication management support system – AdAM 
 
Dear patient,  
Nowadays effective medications are available for the treatment of many illnesses, and it is sometimes 
necessary that you take a number of different drugs. The aim of the AdAM project is to help ensure 
that your drugs are carefully selected to avoid unwanted interactions when you take them. 
In the following pages, we will explain the project to you and request that you agree to take part in it. 
The project will be conducted in Westphalia-Lippe and will be scientifically evaluated. 
 
What is the aim of the project? 
The BARMER health insurance fund and the Westphalia-Lippe Association of Statutory Health 
Insurance (SHI) Physicians intend that the AdAM project should further improve the safety of patients 
taking a number of medications at the same time, and help doctors in the treatment of their patients.  
What is new about this project is that your family practitioner will be able to retrieve electronic 
information from the BARMER database. With the help of these data, participating doctors will gain a 
more comprehensive overview of all their patients’ treatments and prescriptions. Specifically, your 
family practitioner can access information on the medications, remedies and aids that you have been 
prescribed in the last 36 months, as well as the diagnoses and treatments that have been documented 
in the system, including those by other doctors.  
All this information will make it easier to check your drug therapy for possible interactions and 
intolerances. Additionally, you will receive a medication plan with the names of your medications, 
dosage information, and further easy-to-understand information on taking your drugs.  
In order that doctors can call up the required data, every participating practice is electronically linked to 
an assigned BARMER computer via the Association of SHI Physicians (gkvi, based in Wuppertal, 
www.gkvi.de). 
 
Who is eligible to participate in the project? 
All patients insured by BARMER may participate in the project and receive treatment from one of the 
participating family practitioners. To be eligible for participation, patients must be taking three 
prescription medications.  
 
How and what will be scientifically evaluated? 
On the one hand, the project will evaluate whether the intervention has enabled hospitalization to be 
avoided and whether it has led to any changes in drug therapies (project phase 1). On the other hand, 
the project will check whether these changes have been lasting (project phase 2). 
As the first phase of the project is a so-called cluster-randomized study, only half of the participating 
doctors and their patients may participate in the intervention. It is important to separate the doctors 
into an intervention group and a control group to determine whether the project has any influence on 
the success of the therapy. In the second phase of the project, the investigation will aim to determine 
whether any changes are lasting. In this phase, which will begin after 15 months, doctors in the control 
group and their patients may also participate in the project intervention.  
 
What is the actual project procedure?  
After your doctor has provided you with detailed information and you have read this patient information 
leaflet, you can provide your written agreement to participate. Subsequently, your family practitioner 
will immediately be able to retrieve and use data on your treatments that are stored in the BARMER 
computer. This will be made possible using a particularly secure connection between the family 
practice and the BARMER computer via the Westphalia-Lippe Association of SHI Physicians (KVWL, 
based in Dortmund). 
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The data stored in the BARMER computer and the current status of your treatment will then be 
compared and updated on the basis of a personal consultation with your doctor in the family practice. 
After the consultation, the family practitioner will use a computer program that has been specially 
developed for the project to check your drug therapy for any unwanted interactions. 
Should it be necessary, the doctor will contact medical specialists that are treating you and agree on 
changes to your medication. Afterwards, patients will receive a medication plan that has been updated 
according to your needs, and which includes all important information.  
 
Will my participation in the project cost anything? 
Participation in the project is free of charge for patients.  
 
Can I end my participation in the project prematurely? 
The agreement to participate can be withdrawn at any time without providing reasons for doing so, and 
will not have any negative effects on your medical treatment. It is simply necessary to state that you 
wish to cancel your participation in written form and send the cancellation letter to BARMER at the 
following address: 
 
BARMER, Subject: AdAM project, Lichtscheider Str. 89, 42285 Wuppertal 
 
What will happen to my data? 
The family practitioner is the only person to have complete access to patients’ treatment data stored at 
BARMER, and you have signed the agreement to participate only with reference to your family 
practitioner.  
The data used in the project will be transmitted and stored in encrypted form. Family practitioners can 
only make changes to data they have entered into the database during the course of the project.  
Your family practice will transmit your signed declaration of consent and agreement to participate to 
the Westphalia-Lippe Association of SHI Physicians where it will be stored electronically. The signed 
document will then be forwarded to BARMER. All participating patients will be registered with the 
Westphalia-Lippe Association of SHI Physicians and the BARMER insurance fund for the purpose of 
carrying out the project, as well as healthcare accounting. 
Your family practitioner will be permitted to access all the medical data stored at BARMER for a period 
of up to three years. The data will include an overview of all the doctors that have treated you, 
including their documented diagnoses, all prescription invoices and information on hospitalization 
(inpatient diagnoses, dates of admission and discharge, name of the hospital). You have the right to   
see, correct and delete data that has been entered into the database by the doctor, as well as the right 
to object to specific data and the right to data portability.  
The data on participating patients will be made available to the universities that have been 
commissioned to conduct the scientific evaluation in pseudonymized form. Pseudonymized means 
that names and other personally identifiable information (e.g., social insurance number) will be 
replaced with artificial identifiers, so that research scientists are unable to recognize the specific 
person that is referred to.  
Should a participating patient file an objection, or wish to discontinue participation in the project, or if 
the contract with the Westphalia-Lippe Association of SHI Physicians is cancelled, all data that have 
been collected as part of the project will, on receipt of the corresponding notification, be deleted.  
 
Who do I contact if I have any further questions? 
If you have any further questions, please call the toll-free telephone number 0800 333 004 327 331 
from a German fixed or mobile phone network. 
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DECLARATION OF CONSENT AND AGREEMENT TO PARTICIPATE IN THE 
PROJECT 
Application of an electronic medication management support system 
 
The Westphalia-Lippe Association of Statutory Health Insurance Physicians (KVWL) and the BARMER 
health insurance fund have signed a contract for the application of an electronic medication 
management support system. In abbreviated form, the project is also known as AdAM. 
Declaration of consent and agreement to participate 
I have been extensively and comprehensively informed about the nature, significance and implications 
of the AdAM project. I have read and understood the text of the patient information leaflet. I had the 
opportunity to discuss the implementation of the project with my family practitioner. All my questions 
were answered to my satisfaction.  
I agree to permit my doctor to retrieve data on my invoiced treatments and drug prescriptions from all 
physicians that have treated me over the past 36 months on an ongoing basis. I would like my doctor 
to comprehensively check my medication on the basis of a cross-physician overview of all my 
treatment data. My family practitioner will also receive information on my hospitalizations, including 
diagnoses documented by hospitals, as well as, for example, invoiced prescriptions for remedies and 
medical aids, and nursing care. I am pleased that my doctor will be supported by BARMER in my 
medication and care management. 
If necessary, I consent to my doctor contacting my other medical specialists in order to discuss my 
drug therapy.  
My participation in this project is voluntary. Participation under the conditions of the contract begins 
when I sign this declaration of consent. My participation ends when I revoke or cancel this declaration, 
when the contract expires, or if I am no longer insured by BARMER. 
I also agree that the Westphalia-Lippe Association of Statutory Health Insurance Physicians (KVWL, 
based in Dortmund) and BARMER should collect, process and otherwise use my data in order to carry 
out this project, as well as for healthcare accounting. This agreement to participate will be 
electronically recorded at KVWL and transmitted to BARMER. KVWL and BARMER will treat my data 
confidentially and in compliance with prevailing data protection regulations. 
 
Cancellation policy  
I can cancel my participation within two weeks of signing an agreement to participate without providing 
reasons. To meet the deadline, it is sufficient that notice of cancellation is sent to BARMER in due 
time. After the deadline has expired, it remains possible to cancel participation in the project. In order 
to provide notice or cancel, a notice of cancellation should be sent in written form to the following 
address: 







Participating doctor’s personal seal 
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Additional file 3. RpDoc® medical database 
Screening for and assessment of drug interactions 
 
Goal setting 
The medical-scientific editorial team of RpDoc® Solutions GmbH identifies drug interactions by 
continuously monitoring medical-scientific publications and the notifications of national and 
international regulatory authorities. A structured process is then employed to systematically analyze 
and assess them. To help doctors and pharmacists analyze and evaluate drug therapies, the updated 
knowledge of management options concerning clinically relevant interactions is then summarized 
and the interactions and management options, along with references, entered into the RpDoc® 
medical database. 
In addition, the RpDoc® medical database contains recommendations made to avoid specific drug 
combinations that may result from the parallel application of guidelines for individual diseases in 
patients with multimorbidity. These recommendations have been unanimously agreed upon by 
medical and pharmaceutical societies and are published as S2K Guidelines by the AWMF Working 
Group of Scientific Medical Societies. 
The basic principles of screening for and evaluating interactions for the RpDoc® medical databases 
are presented below. 
 
Screening for interactions 
The medical-scientific editorial team of RpDoc® Solutions GmbH monitors more than 8,000 peer-
reviewed scientific journals listed in the EMBASE or the PUBMED database every week. Risk warnings 
issued by American and European regulatory authorities for medicinal products, the FDA and EMA, as 
well as by the German Federal authorities responsible for pharmaceuticals, the Federal Institute for 
Drugs and Medical Devices (BfArM), and the Paul-Ehrlich Institute, are also monitored weekly. Risk 
warnings issued by the Drug Commission of the German Medical Association (AkdÄ) and the Drug 
Commission of German Pharmacists (AMK) are also taken into account. 
 
Assessment of causality 
The WHO UMC algorithm is used to evaluate the causality of adverse drug reactions and the 
information entered into the RpDoc® medical database. 
The various methodological approaches available to categorize the causality of adverse drug 
reactions were compared in a review published in 2018[1]. The WHO algorithm (WHO-UMC) proved 
to be the most suitable for assessing the causality of adverse drug reactions resulting from drug 
interactions. It was developed for the International Drug Monitoring Program by the WHO, in 
collaboration with national pharmacovigilance centers, and is also suitable for the assessment of 
warning signals stemming from case reports [2]. In contrast to the Naranjo algorithm, WHO-UMC is 
also suitable for assessing organ toxicity, side effects of overdoses, and drug interactions [3, 4]. 
DIPS (Drug Interaction Probability Scale) criteria were used to evaluate case descriptions of drug 
interactions [5]. 
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Assessment of quality of evidence 
The evaluation of quality of evidence is based on the GRADE system (Grading of recommendations 
Assessment, Development and Evaluation) [6]. In evidence evaluations, prospective randomized 
studies and meta-analyzes are generally assumed to provide high quality evidence. However, 
indications of adverse drug interactions are often found in case reports and non-randomized studies. 
Such warnings as those found in Dear Doctor letters from pharmaceutical manufacturers and drug 
safety mails from the Drug Commission of the German Medical Association can nevertheless be 
plausible and justify strong recommendations on how to avoid a specific risk. 
In the absence of randomized studies, GRADE can still be used. The instrument of “Good Practice 
Statements" is suitable for situations in which no prospective randomized studies exist, but 
convincing indirect evidence is available [7]. Good practice statements can justify strong 
recommendations even if no randomized studies exist, as long as indirect evidence unequivocally 
supports the recommendation, and other criteria are met [7]. In this case, different sources of 
evidence can be informally linked (linked evidence) to one another in order to provide information 
on net benefit [7]. 
 
An example of an evaluation of clinical relevance 
For liability reasons, pharmaceutical manufacturers provide information on every conceivable risk 
associated with the use of their drugs, both individually and in combination with other medications, 
regardless of clinical relevance. When analyzing a drug therapy, consideration of these risk warnings 
will result in consideration of a high proportion of irrelevant warnings ("alert overkill") [8]. In order to 
achieve practical relevance, it is necessary to limit warnings to those that are clinically relevant, i.e. 
to warnings that should be considered when making therapy decisions [9, 10]. The resulting 
difference is illustrated in the following example: 
Product information (Section 4.5) on siponimod (Mayzent) notes that siponimod should not be 
administered in combination with medicines that “prolong the QT interval". It is only logical that this 
contraindication is consistently found in databases that contain product information, e.g. in the IBM 
Micormedex database (classified as "major" = red). 
Studies have been submitted by the pharmaceutical company for approval and are available in the 
European Product Assessment Report of the EMA. These clearly show that siponimod does not 
increase the QT interval: “A thorough QT study was conducted (study A2118). No effect of siponimod 
on the QTc interval was detected. ... metabolites are not expected to have significant effects on the 
QTc interval. "(EMA / CHMP / 652767/2019). 
However, the studies also show that siponimod lowers the heart rate. A reduction in heart rate 
extends the intervals measured by ECGs, including the QT interval, but not the frequency-corrected 
QT interval that determines the risk of sudden cardiac death. The RpDoc® medical database 
therefore includes no warning against administering siponimod at the same time as QT interval 
prolonging drugs, but rather against drugs that may result in additive heart rate reduction. 
  
Design of the recommendations 
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The design of recommendations has a significant influence on their applicability and effectiveness in 
practice. In order to facilitate the implementation of recommendations, management options aimed 
at minimizing risks should be provided in addition to descriptions of avoidable risks [11]. When a 
warning has high specificity, e.g. because it names particularly affected patient groups or dosages, its 
effectiveness is increased [10]. 
When formulating recommendations for action, the recommendations developed by a group of 
experts on the content of interaction warnings are taken into account [12]. In addition to information 
on the unwanted effects of a specific drug combination, information on predisposing and risk-
minimizing factors, the incidence of adverse effects, and the level of evidence concerning the risk of 
interaction, are also provided. Pharmacological plausibility and the mechanism of interaction are 
presented in addition to management options. In particular, references are made to equivalent 
therapeutic alternatives, as well as recommended surveillance measures in case the drug 
combination is maintained.  
 
Recommendations for action on drug therapies in multimorbidity 
There are guidelines for the evidence-based treatment of numerous diseases, but the parallel 
application of guidelines for each individual disease can, in multimorbidity, lead to unfavorable and 
risky drug combinations [13]. 
To resolve these therapeutic conflicts, medical and pharmaceutical scientific societies develop 
recommendations for action that the AWMF, with the support of the AdAM and TOP innovation fund 
projects, publishes in S2K Guidelines. RpDoc® Solutions GmbH is involved in both these innovation 
fund projects as a technology partner, and recommendations developed for drug therapies in 
multimorbidity are continuously updated in the RpDoc® medical database. 
For an overview of the AdAM and TOP projects, please see the brief summary provided by the joint 
federal committee (https://innovationsfonds.g-ba.de/). 
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TIDieR checklist         
 
 
WHEN and HOW MUCH 
  
8. Describe the number of times the intervention was delivered and over what period of time including 
the number of sessions, their schedule, and their duration, intensity or dose. 
16 _____________ 
 TAILORING   
9. If the intervention was planned to be personalised, titrated or adapted, then describe what, why, 
when, and how. 
N/A _____________ 
 MODIFICATIONS   
10.
ǂ
 If the intervention was modified during the course of the study, describe the changes (what, why, 
when, and how). 
N/A _____________ 
 HOW WELL   
11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any 






Actual: If intervention adherence or fidelity was assessed, describe the extent to which the 
intervention was delivered as planned. 
N/A _____________ 
** Authors - use N/A if an item is not applicable for the intervention being described. Reviewers – use ‘?’ if information about the element is not reported/not   
sufficiently reported.         
† If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol      
or other published papers (provide citation details) or a website (provide the URL). 
ǂ If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete. 
* We strongly recommend using this checklist in conjunction with the TIDieR guide (see BMJ 2014;348:g1687) which contains an explanation and elaboration for each item. 
* The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of 
studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a randomised trial is being reported, the 
TIDieR checklist should be used in conjunction with the CONSORT statement (see www.consort-statement.org) as an extension of Item 5 of the CONSORT 2010 Statement. 
When a clinical trial protocol is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of Item 11 of the SPIRIT 2013 
Statement (see www.spirit-statement.org). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see 
www.equator-network.org).  
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Additional file 5. Specifications related to the secondary outcome measures 
Each of the condition listed (•) must be met for the respective secondary outcome to be 
fulfilled. 
SOpim-1: 
• Diagnosed with any of the following ICD-10: K20-21, K25-28 
• Prescribed ATC M01A (except M01AB55 and M01AE52) 
• Not prescribed ATC A02B 
SOpim-2: 
• Age 65+ 
• Prescribed ATC M01A (except M01AB55 and M01AE52) 
• Not prescribed ATC A02B 
SOpim-3 
• Prescribed ATC B01AC 
• Prescribed ATC M01A (except M01AB55 and M01AE52) 
• Not prescribed ATC A02B 
SOpim-4 
• Prescribed either ATC B01AC34 or a combination of ATC B01AC06 with any of the 
following 
ATC: B01AC04, B01AC24, B01AC22 
• Not prescribed ATC A02B 
SOpim-5 
• Prescribed any of the following ATC: B01AA, B01AE, B01AF 
• Prescribed ATC M01A (except M01AB55 and M01AE52) 
• Not prescribed ATC A02B 
SOpim-6 
• Prescribed ATC B01AA 
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• Prescribed ATC B01AC 
• Not prescribed ATC A02B 
SOpim-7 
• Prescribed any of the following ATC: G04BX18, N06AB, N06AX16, N06AX17, N06AX21 
• Prescribed ATC M01A (except M01AB55 and M01AE52) 
• Not prescribed ATC A02B 
SOpim-8 
• Prescribed any of the following ATC: H02AB, H02BX 
• Prescribed ATC M01A (except M01AB55 and M01AE52) 
• Not prescribed ATC A02B 
SOpim-9 
• Prescribed ATC C09 
• Prescribed ATC M01 
SOpim-10 
• Prescribed any of the following ATC: C03AA, C03BA, C03CA, C03D, C03E 
• Prescribed ATC M01A 
SOpim-11 
• Diagnosed with ICD-10 I50 
• Prescribed ATC M01A 
SOpim-12 
• Diagnosed with ICD-10 I50 
• Prescribed ATC N06AA 
SOpim-13 
• Prescribed any of the following ATC: C03D, C09 
• Prescribed ATC A12BA 
SOpim-14 
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• Diagnosed with ICD-10 I50 
• Prescribed any of the following ATC: C07AA, C07BA, C07DA, S01ED (except S01ED02) 
SOpim-15 
• Age 65+ 
• Prescribed any of the following ATC: A03FA03, A04AA01, B01AC23, C01BC04, 
C01BD01, C01BD07, C07AA07, C08DA81, H01BA04, L01XE12, L01XX35, N05AA02, 
N05AC02, N05AD01, N05AD08, N05AF03, N05AG02, N05AL01, N06AB04, N06AB10, 
N06DA02, N07BC02, P01BA01, P01BA02 
SOpim-16 
• Any of the following: 
1. 
• Prescribed any two of the following ATC: A03FA03, A04AA01, B01AC23, C01BC04, 
C01BD01, C01BD07, C07AA07, C08DA81, H01BA04, L01XE12, L01XX35, N05AA02, 
N05AC02, N05AD01, N05AD08, N05AF03, N05AG02, N05AL01, N06AB04, N06AB10, 
N06DA02, N07BC02, P01BA01, P01BA02 
2. 
• Prescribed any of the following ATC: C01BC04, N05AC02, N06DA02, A04AA01, 
N05AD01, N06AB04, N06AB10 
• Prescribed any of the following ATC: A08AA62, N06AX12, N07BA02, H05BX01, 
N06AB03, N06AB05, C08DA81 
3. 
• Prescribed any of the following ATC: A04AA01, N05AD01, N06AB04, N06AB10, 
A03FA03, B01AC23, C08DA81, N05AG02, N07BC02 
• Prescribed any of the following ATC: A02BD04, A02BD05, J01FA09, J05AE02, 
J02AC02, J02AB02, J05AE03, J05AP53, J05AR10, J05AE01, L01XX47, L01XE42, 
J01FA15 
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4. 
• Diagnosed with any of the following ICD-10: I50, R00.1, I49.5, I49.8 
• Prescribed any of the following ATC: A03FA03, A04AA01, B01AC23, C01BC04, 
C01BD01, C01BD07, C07AA07, C08DA81, H01BA04, L01XE12, L01XX35, N05AA02, 
N05AC02, N05AD01, N05AD08, N05AF03, N05AG02, N05AL01, N06AB04, N06AB10, 
N06DA02, N07BC02, P01BA01, P01BA02 
SOpim-17 
• Prescribed ATC C01AA 
• Prescribed any of the following ATC: C03AA, C03BA, C03CA, C07B, C07C, C08GA23, 
C09BA, C09BX01, C09BX03, C09DA, C09DX01, C09DX03, C09DX06, C09DX07, C09XA52, 
C09XA54 
• Not prescribed ATC A12BA 
SOpim-18 
• Age 65+ 
• Prescribed any of the following ATC: A03CA02, C04AD03, C04AE01, C04AE02, 
C04AE04, C04AE54, C04AX01, C04AX07, C04AX10, C04AX17, C04AX20, C04AX21, 
C05CA05, C05CA07, C05CA51, C05CA54, M03BA02, M03BA03, M03BC01, M03BX01, 
M03BX02, M03BX07, M03BX08, N02AB02, N03AE01, N04AA01, N04AA02, N04AA12, 
N04AC01, N04BB01, N04BC08, N05AA01, N05AA02, N05AA04, N05BA05, N05AB02, 
N05AB03, N05AB04, N05AC01, N05AC02, N05AD01, N05AD08, N05AE03, N05AF05, 
N05AG02, N05AH02, N05AH03, N05BA01, N05BA02, N05BA03, N05BA04, N05BA05, 
N05BA06, N05BA08, N05BA09, N05BA11, N05BA12, N05BA13, N05BA16, N05BA18, 
N05BA21, N05CD01, N05CD02, N05CD03, N05CD04, N05CD05, N05CD06, N05CD07, 
N05CD08, N05CD09, N05CD10, N05CD11, N05CF01, N05CF02, N05CF03, N06AA01, 
N06AA02, N06AA04, N06AA06, N06AA09, N06AA10, N06AA12, N06AA21, N06AB05, 
N06AB08, N06AX16, N06DX02 
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SOpim-19 
• Diagnosed with any of the following ICD-10: G20-23 
• Prescribed any of the following ATC: A03CA02, C04AD03, C04AE01, C04AE02, 
C04AE04, C04AE54, C04AX01, C04AX07, C04AX10, C04AX17, C04AX20, C04AX21, 
C05CA05, C05CA07, C05CA51, C05CA54, M03BA02, M03BA03, M03BC01, M03BX01, 
M03BX02, M03BX07, M03BX08, N02AB02, N03AE01, N04AA01, N04AA02, N04AA12, 
N04AC01, N04BB01, N04BC08, N05AA01, N05AA02, N05AA04, N05BA05, N05AB02, 
N05AB03, N05AB04, N05AC01, N05AC02, N05AD01, N05AD08, N05AE03, N05AF05, 
N05AG02, N05AH02, N05AH03, N05BA01, N05BA02, N05BA03, N05BA04, N05BA05, 
N05BA06, N05BA08, N05BA09, N05BA11, N05BA12, N05BA13, N05BA16, N05BA18, 
N05BA21, N05CD01, N05CD02, N05CD03, N05CD04, N05CD05, N05CD06, N05CD07, 
N05CD08, N05CD09, N05CD10, N05CD11, N05CF01, N05CF02, N05CF03, N06AA01, 
N06AA02, N06AA04, N06AA06, N06AA09, N06AA10, N06AA12, N06AA21, N06AB05, 
N06AB08, N06AX16, N06DX02 
SOum-1 
• Diagnosed with ICD-10 I48 
• Not prescribed any of the following ATC: B01AA, B01AE, B01AF 
SOum-2 
• Diagnosed with any of the following ICD-10: I20-I22, I24-25, I63-66, I69, I70-72, I74 
• Not prescribed any of the following ATC: B01AC04, B01AC06, B01AC22, B01AC24, 
B01AC34, B01AC36 
SOum-3 
• Diagnosed with any of the following ICD-10: I20-25 
• Not prescribed ATC C07 
SOum-4 
• Prescribed any of the following ATC: L01BA01, L04AX03, M01CX01 
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• Not prescribed ATC B03BB 
SOum-5 
• Prescribed ATC N02A (except N02AA55 and N02AX51) 
• Not prescribed any of the following ATC: A06AB, A06AD, A06AH 
SOum-6 
• Diagnosed with any of the following ICD-10: I20-25, I50 
• Not prescribed ATC C09 (except C09X) 
SOum-7 
• Diagnosed with ICD-10 I50 
• Not prescribed any of the following ATC: C07AB02, C07AB07, C07AB12, C07AG02, 
C07BB02, C07BB07, C07BB12, C07BB22, C07BB27, C07BB52, C07BG02 C07CB02, 
C07CB22, C07FB02, C07FB07, C07FB12, C07FB13, C07FB22, C07FX03, C07FX04, 
C07FX05, C07FX06 
SOum-8 
• Diagnosed with any of the following ICD-10: J44-45 
• Not prescribed any of the following ATC: R03AC, R03AK, R03AL, R03BB 
SOum-9 
• Diagnosed with any of the following ICD-10: J44-45 
• Not prescribed any of the following ATC: R03AK (except R03AK01, R03AK02, 
R03AK03, R03AK04 and R03AK05), R03AL08, R03AL09, R03BA 
SOum-10 
• Diagnosed with any of the following ICD-10: E10-11, E14 
• Not prescribed ATC C09 (except C09X) 
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Additional file 6. CONSORT 2010 checklist of information to include when reporting a 
cluster randomised trial  
Section/Topic Item 
No 




Title and abstract  
 
1a Identification as a 
randomised trial in the title 
Identification as a cluster 
randomised trial in the title 
1 
1b Structured summary of trial 
design, methods, results, 
and conclusions (for specific 
guidance see CONSORT for 
abstracts)1,2 




2a Scientific background and 
explanation of rationale 
Rationale for using a cluster 
design 
9 
2b Specific objectives or 
hypotheses 
Whether objectives pertain to 
the cluster level, the individual 
participant level or both 
10 
Methods  
Trial design 3a Description of trial design 
(such as parallel, factorial) 
including allocation ratio 
Definition of cluster and 
description of how the design 
features apply to the clusters 
11 
3b Important changes to 
methods after trial 
commencement (such as 




Participants 4a Eligibility criteria for 
participants 
Eligibility criteria for clusters  11 
4b Settings and locations 




Interventions 5 The interventions for each 
group with sufficient details 
to allow replication, 
including how and when 
they were actually 
administered 
Whether interventions pertain to 
the cluster level, the individual 
participant level or both 
14 
Outcomes 6a Completely defined pre-
specified primary and 
Whether outcome measures 
pertain to the  cluster level, the 
16 
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secondary outcome 
measures, including how 
and when they were 
assessed 
individual participant level or 
both 
6b Any changes to trial 
outcomes after the trial 
commenced, with reasons 
 
NA 
Sample size 7a How sample size was 
determined 
Method of calculation, number 
of clusters(s) (and whether equal 
or unequal cluster sizes are 
assumed), cluster size, a 
coefficient of intracluster 
correlation (ICC or k), and an 
indication of its uncertainty 
21 
7b When applicable, 
explanation of any interim 







8a Method used to generate 




8b Type of randomisation; 
details of any restriction 
(such as blocking and block 
size) 
Details of stratification or 





9 Mechanism used to 
implement the random 
allocation sequence (such as 
sequentially numbered 
containers), describing any 
steps taken to conceal the 
sequence until interventions 
were assigned 
Specification that allocation was 
based on clusters rather than 
individuals and whether 
allocation concealment (if any) 
was at the cluster level, the 





10 Who generated the random 
allocation sequence, who 
enrolled participants, and 
who assigned participants 
to interventions 




Who generated the random 
allocation sequence, who 
enrolled clusters, and who 
assigned clusters to interventions 
 
12-14 
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Mechanism by which individual 
participants were included in 
clusters for the purposes of the 
trial (such as complete 





From whom consent was sought 
(representatives of the cluster, or 
individual cluster members, or 
both), and whether consent was 




    
 
Blinding 11a If done, who was blinded 
after assignment to 
interventions (for example, 
participants, care providers, 




11b If relevant, description of 






12a Statistical methods used to 
compare groups for primary 
and secondary outcomes 
How clustering was taken into 
account 
21 
12b Methods for additional 
analyses, such as subgroup 









13a For each group, the 
numbers of participants 
who were randomly 
assigned, received intended 
treatment, and were 
analysed for the primary 
outcome 
For each group, the numbers of 
clusters that were randomly 
assigned, received intended 
treatment, and were analysed for 
the primary outcome 
NA 




For each group, losses and 
exclusions for both clusters and 
individual cluster members 
NA 
Recruitment 14a Dates defining the periods 
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Baseline data 15 A table showing baseline 
demographic and clinical 
characteristics for each 
group 
Baseline characteristics for the 
individual and cluster levels as 
applicable for each group 
NA 
Numbers analysed 16 For each group, number of 
participants (denominator) 
included in each analysis 
and whether the analysis 
was by original assigned 
groups 
For each group, number of 




17a For each primary and 
secondary outcome, results 
for each group, and the 
estimated effect size and its 
precision (such as 95% 
confidence interval) 
Results at the individual or 
cluster level as applicable and a 
coefficient of intracluster 
correlation (ICC or k) for each 
primary outcome 
NA 
17b For binary outcomes, 
presentation of both 
absolute and relative effect 
sizes is recommended 
 
NA 
Ancillary analyses 18 Results of any other 
analyses performed, 
including subgroup analyses 





Harms 19 All important harms or 
unintended effects in each 
group (for specific guidance 




Limitations 20 Trial limitations, addressing 
sources of potential bias, 
imprecision, and, if relevant, 
multiplicity of analyses 
 
25 
Generalisability 21 Generalisability (external 
validity, applicability) of the 
trial findings 
Generalisability to clusters 
and/or individual participants (as 
relevant) 
NA 
Interpretation 22 Interpretation consistent 
with results, balancing 
benefits and harms, and 
 
NA 
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Registration 23 Registration number and 
name of trial registry 
 
7 
Protocol 24 Where the full trial protocol 
can be accessed, if available 
 
NA 
Funding 25 Sources of funding and 
other support (such as 




* Note: page numbers optional depending on journal requirements 
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Additional file 7. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial 




Administrative information  
Title 1 Descriptive title identifying the study design, 





2a Trial identifier and registry name. If not yet 
registered, name of intended registry 
8 
2b All items from the World Health Organization Trial 




3 Date and version identifier 34 






5a Names, affiliations, and roles of protocol 
contributors 
33 
5b Name and contact information for the trial sponsor 33-34 
 5c Role of study sponsor and funders, if any, in study 
design; collection, management, analysis, and 
interpretation of data; writing of the report; and the 
decision to submit the report for publication, 
including whether they will have ultimate authority 
over any of these activities 
34 
 5d Composition, roles, and responsibilities of the 
coordinating centre, steering committee, endpoint 
adjudication committee, data management team, 
and other individuals or groups overseeing the trial, 
if applicable (see Item 21a for data monitoring 
committee) 
33 
Introduction    
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6a Description of research question and justification 
for undertaking the trial, including summary of 
relevant studies (published and unpublished) 
examining benefits and harms for each intervention 
11-13 
 6b Explanation for choice of comparators 11-13 
Objectives 7 Specific objectives or hypotheses 12-13 
Trial design 8 Description of trial design including type of trial (eg, 
parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, 
equivalence, noninferiority, exploratory) 
13-14 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, 
academic hospital) and list of countries where data 
will be collected. Reference to where list of study 




10 Inclusion and exclusion criteria for participants. If 
applicable, eligibility criteria for study centres and 




Interventions 11a Interventions for each group with sufficient detail to 
allow replication, including how and when they will 
be administered 
17-19 
Additional file 3 
11b Criteria for discontinuing or modifying allocated 
interventions for a given trial participant (eg, drug 
dose change in response to harms, participant 
request, or improving/worsening disease) 
23 
11c Strategies to improve adherence to intervention 
protocols, and any procedures for monitoring 
adherence (eg, drug tablet return, laboratory tests) 
17-19 
11d Relevant concomitant care and interventions that 
are permitted or prohibited during the trial 
17-19 
Outcomes 12 Primary, secondary, and other outcomes, including 
the specific measurement variable (eg, systolic 
blood pressure), analysis metric (eg, change from 
baseline, final value, time to event), method of 
aggregation (eg, median, proportion), and time 
point for each outcome. Explanation of the clinical 
relevance of chosen efficacy and harm outcomes 
is strongly recommended 
19-21 
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13 Time schedule of enrolment, interventions 
(including any run-ins and washouts), 
assessments, and visits for participants. A 




Sample size 14 Estimated number of participants needed to 
achieve study objectives and how it was 
determined, including clinical and statistical 
assumptions supporting any sample size 
calculations 
24 
Recruitment 15 Strategies for achieving adequate participant 
enrolment to reach target sample size 
24 
Methods: Assignment of interventions (for controlled trials)  
Allocation:    
Sequence 
generation 
16a Method of generating the allocation sequence (eg, 
computer-generated random numbers), and list of 
any factors for stratification. To reduce 
predictability of a random sequence, details of any 
planned restriction (eg, blocking) should be 
provided in a separate document that is 








16b Mechanism of implementing the allocation 
sequence (eg, central telephone; sequentially 
numbered, opaque, sealed envelopes), describing 
any steps to conceal the sequence until 




16c Who will generate the allocation sequence, who 
will enrol participants, and who will assign 




17a Who will be blinded after assignment to 
interventions (eg, trial participants, care providers, 
outcome assessors, data analysts), and how 
 
 17b If blinded, circumstances under which unblinding is 
permissible, and procedure for revealing a 
participant’s allocated intervention during the trial 
 
Methods: Data collection, management, and analysis  
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18a Plans for assessment and collection of outcome, 
baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate 
measurements, training of assessors) and a 
description of study instruments (eg, 
questionnaires, laboratory tests) along with their 
reliability and validity, if known. Reference to where 
data collection forms can be found, if not in the 
protocol 
22-24 
 18b Plans to promote participant retention and 
complete follow-up, including list of any outcome 
data to be collected for participants who 




19 Plans for data entry, coding, security, and storage, 
including any related processes to promote data 
quality (eg, double data entry; range checks for 
data values). Reference to where details of data 





20a Statistical methods for analysing primary and 
secondary outcomes. Reference to where other 
details of the statistical analysis plan can be found, 
if not in the protocol 
24-25 
 20b Methods for any additional analyses (eg, subgroup 
and adjusted analyses) 
24-25 
 20c Definition of analysis population relating to protocol 
non-adherence (eg, as randomised analysis), and 
any statistical methods to handle missing data (eg, 
multiple imputation) 
24-25 
Methods: Monitoring  
Data 
monitoring 
21a Composition of data monitoring committee (DMC); 
summary of its role and reporting structure; 
statement of whether it is independent from the 
sponsor and competing interests; and reference to 
where further details about its charter can be 
found, if not in the protocol. Alternatively, an 
explanation of why a DMC is not needed 
21-22 
 21b Description of any interim analyses and stopping 
guidelines, including who will have access to these 
interim results and make the final decision to 
terminate the trial 
21-22 
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Harms 22 Plans for collecting, assessing, reporting, and 
managing solicited and spontaneously reported 
adverse events and other unintended effects of 
trial interventions or trial conduct 
21-22 
Auditing 23 Frequency and procedures for auditing trial 
conduct, if any, and whether the process will be 
independent from investigators and the sponsor 
21-22 




24 Plans for seeking research ethics 





25 Plans for communicating important protocol 
modifications (eg, changes to eligibility criteria, 
outcomes, analyses) to relevant parties (eg, 
investigators, REC/IRBs, trial participants, trial 




26a Who will obtain informed consent or assent from 
potential trial participants or authorised surrogates, 
and how (see Item 32) 
17-19 
 26b Additional consent provisions for collection and use 
of participant data and biological specimens in 




27 How personal information about potential and 
enrolled participants will be collected, shared, and 
maintained in order to protect confidentiality 




28 Financial and other competing interests for 





29 Statement of who will have access to the final trial 
dataset, and disclosure of contractual agreements 




30 Provisions, if any, for ancillary and post-trial care, 
and for compensation to those who suffer harm 
from trial participation 
21-22 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open




31a Plans for investigators and sponsor to 
communicate trial results to participants, 
healthcare professionals, the public, and other 
relevant groups (eg, via publication, reporting in 
results databases, or other data sharing 
arrangements), including any publication 
restrictions 
28 
 31b Authorship eligibility guidelines and any intended 
use of professional writers 
nr 
 31c Plans, if any, for granting public access to the full 
protocol, participant-level dataset, and statistical 
code 
34 




32 Model consent form and other related 
documentation given to participants and authorised 
surrogates 
Additional file 5 
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and 
storage of biological specimens for genetic or 
molecular analysis in the current trial and for future 
use in ancillary studies, if applicable 
nr 
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 
Explanation & Elaboration for important clarification on the items. Amendments to the 
protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT 
Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” 
license. 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-048191:e048191. 11 2021;BMJ Open, et al. Müller BS
